Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1650 USD | -11.58% |
|
-96.84% | -97.24% |
02-06 | BioXcel to Implement Reverse Stock Split; Shares Fall | MT |
02-05 | BioXcel Therapeutics Provides Clinical and Business Update | RE |
Highlights: BioXcel Therapeutics
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: BioXcel Therapeutics
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings Chart: BioXcel Therapeutics
ESG chart: BioXcel Therapeutics
Financials
Valuation
Revisions
Consensus
Business Predictability
ESG
- Stock Market
- Equities
- BTAI Stock
- Ratings BioXcel Therapeutics

MarketScreener is also available in this country: United States.
Switch edition